IDYA IDEAYA Biosciences, Inc. Common Stock
XNAS
35.47
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
IDYA
$35.47
—
Key stats
$35.47
Pre-market
$35.35
-0.34%
- 52-Week Range
- $26.81 – $42.68
- YTD
- +4.79%
- IV Rank (30D)
- 36.67
- Straddle Price
- $5.15
- P/C Vol Ratio
- 0.14
- Market Cap
- $3.4B
- Open
- $35.43
- Day Range
- $35.33 – $36.11
- Volume
- 648,834
- Prev Close
- $35.36
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.85 |
| Cost of Equity (CAPM) | 9.40% (VRP-adj) |
| WACC | 9.38% |
| Volatility Risk Premium | +55.0pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -14.6% |
| Book / Price | 37.7% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -48.6% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $37.77 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $36.09 |
| Bollinger Width / SMA20 | 49.8% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $3B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
27%
20-Day Fair Value
≈ by Nov 20, 2026
$35.50
α +0.1%
rank 43%
conviction
6%
40-Day Fair Value
≈ by Dec 21, 2026
$35.95
α +1.3%
rank 49%
conviction
43%
60-Day Fair Value
≈ by Jan 19, 2027
$35.73
α +0.7%
rank 40%
conviction
27%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.6× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.0× · 3 peers |
| Peer P/B | $46.36 | 25% | median 3.5× · 3 peers |
| Peer P/S | $9.94 | 25% | median 3.8× · 3 peers |
| Market Anchor (SMA50) | $37.77 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $37.39 | 49% | 15 strikes · skew -0.12 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $3.4B
- Employees
- 145
- List Date
- 2019-05-23
- CIK
- 0001676725
- Next Earnings
- 2026-11-03 (After-Close)
- EPS Forecast
- ($1.26) (5 est.)
- Headquarters
- South San Francisco, CA
- Homepage
- https://www.ideayabio.com
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 30.32% | -31.02% | -2.01% | 23.59% | -3.22% | -4.90% | 2.13% |
| Feb | 5.42% | -22.81% | 2.26% | 0.38% | -12.99% | -5.46% | -5.53% |
| Mar | 20.02% | -12.99% | -21.18% | -5.06% | -14.38% | 0.85% | -5.46% |
| Apr | -13.80% | -15.88% | 24.05% | -4.40% | 36.29% | -10.41% | 2.64% |
| May | -2.80% | 13.54% | 18.04% | -11.24% | -2.83% | 4.54% | 3.21% |
| Jun | 2.59% | 31.43% | -1.76% | -9.72% | -0.94% | 28.78% | 8.40% |
| Jul | 11.97% | 4.19% | -2.23% | 19.85% | 15.29% | -1.88% | 7.87% |
| Aug | 0.13% | -32.21% | 31.01% | -6.97% | 1.15% | 13.28% | 1.07% |
| Sep | 3.79% | 52.24% | -9.37% | -16.87% | 6.79% | -3.83% | 5.46% |
| Oct | -16.05% | 13.89% | 5.19% | -8.40% | 16.45% | -6.19%* | 0.81% |
| Nov | -1.35% | 2.17% | 8.86% | -4.34% | 13.58% | -- | 3.78% |
| Dec | 10.62% | 2.25% | 12.49% | -6.38% | 0.76% | -- | 3.95% |
| Total | 51.09% | -25.60% | 69.89% | -31.39% | 56.98% | 9.66% | 21.77% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $36.09
SMA 50: $37.77
SMA 200: $34.12
Current: $35.47
EMA 12: $35.19
EMA 26: $36.17
MACD: -0.9816 | Signal: -0.0871
BEARISH
ADX (14): 18.82
RANGE
+DI: 21.30
−DI: 25.72
Momentum Oscillators
RSI (14): 45.69
NEUTRAL
Stoch %K: 34.46
Stoch %D: 20.44
Williams %R: -52.95
Volume & Volatility
BB Upper: $39.33
BB Lower: $32.84
NEUTRAL
OBV: 37,913,296
Vol SMA 20: 805,407
Vol ROC: 17.52%
ATR: $1.37
True Range: $0.78
HV 20: 38.3%
HV 30: 37.7%
HV 60: 34.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL (confidence level: 6/10)
Key drivers and primary risks:
- Technical indicators suggest a neutral trend, with RSI indicating a neutral zone.
- Recent news headlines not available, but earnings upcoming.
- Risk metrics show above-average volatility.
Investment thesis: IDYA is trading within a range-bound market environment, with neither strong buying nor selling pressure. Earnings expectations are mixed, which could impact the stock's price movement.
Recent news sentiment impact: With no recent news available, we cannot assess the impact of news on the stock price.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): NEUTRAL
- Medium-term (1-3 months): NEUTRAL
- Long-term (3-12 months): BEARISH
Support/Resistance Levels:
- SMA 20: $27.80 (resistance)
- SMA 50: $26.19 (support)
Momentum Signals:
- RSI interpretation: 60.57 (neutral)
- MACD signal: Bullish momentum
- Bollinger Bands position: Neutral (price within the middle band range)
Volume Analysis:
- Volume trends: Low volume, no clear direction.
- Institutional interest signals: No significant institutional buying or selling.
News & Sentiment Analysis
Recent Headlines Summary: No recent news available.
Sentiment Assessment: N/A
Catalyst Identification:
- Upcoming earnings release on 2025-11-04
- Fiscal period ending in 2025-09-30
Market Narrative: The lack of recent news and upcoming earnings release may impact the stock's price movement, but technical indicators suggest a neutral trend.
Risk & Volatility Assessment
Beta Interpretation: IDYA has a beta of 1.06 relative to SPY, indicating above-average volatility.
Volatility Regime: Current volatility is above average (0.53).
Options Market Signals:
- IV rank: Low (14.7%)
- Put/call ratios: Neutral (0.75)
- Unusual activity: No significant unusual activity detected
Downside Protection:
- Support levels: SMA 50 at $26.19
- Risk management considerations: Stop-loss levels and position sizing to consider.
Market Context & Positioning
Sector Performance:
- IDYA is trading within its sector's performance range.
Institutional Activity:
- No significant institutional buying or selling detected.
Correlation Analysis:
- IDYA has a correlation of 0.39 with SPY, indicating some price movement relative to the market.
Relative Valuation:
- IDYA is positioned within its trading range.
Key Levels & Action Items
Critical Price Levels:
- SMA 20 at $27.80 (resistance)
- SMA 50 at $26.19 (support)
Breakout/Breakdown Levels:
- Upper band: $29.94
- Lower band: $25.66
Time-Sensitive Catalysts:
- Earnings release on 2025-11-04
- Fiscal period ending in 2025-09-30
Risk Management:
- Stop-loss levels and position sizing to consider.
This comprehensive analysis provides an in-depth look at IDYA's technical, news, and risk metrics. The neutral trend suggests a range-bound market environment, with neither strong buying nor selling pressure. Earnings expectations are mixed, which could impact the stock's price movement.
Generated
News
All IDYA news →
Earnings History
16 of 16 under expected move
Avg Expected Move
15.24%
Avg Actual Move
2.84%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-03-15 | After-Close | 40.79% | 0.08% | 0.00x | Within |
| 2022-08-15 | After-Close | 10.78% | 5.29% | 0.49x | Within |
| 2022-11-08 | After-Close | 10.26% | 5.82% | 0.57x | Within |
| 2023-04-24 | After-Close | 18.85% | 8.00% | 0.42x | Within |
| 2023-10-24 | After-Close | 14.42% | 4.40% | 0.31x | Within |
| 2024-02-20 | After-Close | 12.00% | 0.64% | 0.05x | Within |
| 2024-05-07 | After-Close | 12.65% | 3.13% | 0.25x | Within |
| 2024-07-09 | After-Close | 13.98% | 3.37% | 0.24x | Within |
| 2024-11-04 | After-Close | 9.33% | 1.40% | 0.15x | Within |
| 2025-02-13 | Pre-Market | 22.55% | 5.42% | 0.24x | Within |
| 2025-05-06 | After-Close | 21.41% | 0.45% | 0.02x | Within |
| 2025-08-05 | After-Close | 16.17% | 2.03% | 0.13x | Within |
| 2025-11-04 | After-Close | 12.14% | 2.69% | 0.22x | Within |
| 2026-02-17 | After-Close | 10.97% | 0.52% | 0.05x | Within |
| 2026-05-05 | After-Close | 7.73% | 0.21% | 0.03x | Within |
| 2026-08-04 | Pre-Market | 9.82% | 2.01% | 0.20x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
IDYA Options Activity & IV Rank
IDYA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 63.8%
7-DTE IV: —
Expected Move: $5.15
7-DTE Move: $5.15
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 51
Put Volume: 7
P/C Volume: 0.137
BULLISH
Call OI: 121
Put OI: 25
P/C OI: 0.207
Total OI: 146
ATM Options Pricing
ATM Call: $3.50
ATM Put: $1.65
Call %: 9.9%
Put %: 4.7%
Chain Summary
Chain Volume: 393
Chain OI: 1,272
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 72nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
72%
vs own history
GEX tilt
+0.78
OI-weighted, today
Vanna tilt
+0.98
δ-sensitivity to IV
Charm tilt
-0.97
δ-decay vs time
Vanna tilt +0.98: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.97: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 7 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · ATM 63.4% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)36.7MediumOct 21
Straddle Price (30 DTE)$5.15Oct 21
Beta Analysis
Risk Metrics
Beta: 0.9492
Alpha: 15.48%
Correlation: 0.2657
R-Squared: 7.1%
Stock Volatility: 45.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own IDYA
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $11.2M | #1505 of 6285 | -55.8% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $391K | #3263 of 3716 | -95.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $16K | #3817 of 4729 | -19.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
IDYA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 89,734,330 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
7 filers$15.80M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $10.27M | 65.01% | 2026-06-30 |
| 2 | Citigroup Inc. Custodian | $2.99M | 18.90% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $1.03M | 6.54% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $976.47K | 6.18% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $286.98K | 1.82% | 2026-06-30 |
| 6 | PEAK6 LLC | $137.90K | 0.87% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $108.08K | 0.68% | 2026-06-30 |
5 filers$11.05M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $6.37M | 57.59% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $3.02M | 27.31% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $1.44M | 13.01% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $141.63K | 1.28% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $89.45K | 0.81% | 2026-06-30 |
IDYA Insider Trading (Form 4)
Latest: 2026-10-08Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | Yujiro S Hata | President and CEO | Mixed | — | $20.86 | -$871.9K | EDGAR |
| 2026-07-09 | Briseno Andres Ruiz | Chief Accounting Officer | Mixed | — | $26.44 | -$259.3K | EDGAR |
| 2026-06-18 | Malcolm Garret Hampton | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-06-18 | Scott W Morrison | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-06-18 | Wendy L Yarno | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-06-18 | Terry J Rosen | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-06-18 | Catherine J Mackey | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-06-18 | Jeffrey Stein | Director | Grant (A) | +20,000 opt | — | EDGAR | |
| 2026-03-02 | Jeffrey Stein | Director | Buy (P) | +50,000 | $32.96 | $1.65M | EDGAR |
| 2026-02-02 | Darrin Beaupre | Chief Medical Officer | Grant (A) | +175,000 opt | — | EDGAR | |
| 2026-02-02 | Michael Anthony White | Chief Scientific Officer | Grant (A) | +190,000 opt | — | EDGAR | |
| 2026-02-02 | Douglas B. Snyder | SVP, General Counsel | Award (A) | +2,080 | $16.91 | $35.2K | EDGAR |
| 2026-02-02 | Stuart Dorman | Chief Commercial Officer | Grant (A) | +155,000 opt | — | EDGAR | |
| 2026-02-02 | Joshua Bleharski | Chief Financial Officer | Grant (A) | +170,000 opt | — | EDGAR | |
| 2026-02-02 | Yujiro S Hata | President and CEO | Grant (A) | +600,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
IDYA Insider Holdings
5 insiders · @ $35.47
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Yujiro S Hata | President and CEO | 717,033 | $25.43M | -$18.54M | 18 | 2026-10-08 |
| 2 | Jeffrey Stein | Director | 57,644 | $2.04M | $1.65M | 9 | 2026-06-18 |
| 3 | Briseno Andres Ruiz | Chief Accounting Officer | 36,016 | $1.28M | -$762.3K | 9 | 2026-07-09 |
| 4 | Douglas B. Snyder | SVP, General Counsel | 1,039 | $36.9K | $0 | 3 | 2026-02-02 |
| 5 | Michael Anthony White | Chief Scientific Officer | 851 | $30.2K | -$1.03M | 7 | 2026-02-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
IDYA Board & Officers
As of SEC filings through Oct 8, 2026Directors 7
- Jeffrey Stein · since May 22, 2019
- Scott W Morrison · since May 22, 2019
- Terry J Rosen · since May 22, 2019
- Yujiro S Hata · since May 22, 2019
- Wendy L Yarno · since Dec 17, 2019
- Malcolm Garret Hampton · since Jun 26, 2020
- Catherine J Mackey · since Apr 5, 2022
Officers 8
- Yujiro S Hata · President and CEO · since May 22, 2019
- Joshua Bleharski · Chief Financial Officer · since Jun 27, 2025
- Darrin Beaupre · Chief Medical Officer · listed since Feb 2023
- Michael Anthony White · Chief Scientific Officer · listed since Feb 2023
- Stuart Dorman · Chief Commercial Officer · since Dec 11, 2024
- Theodora Ross · Chief Development Officer · since Mar 18, 2026
- Douglas B. Snyder · SVP, General Counsel · since Sep 18, 2024
- Briseno Andres Ruiz · Title: SVP, Head of Finance and Investor Relations · since Jul 1, 2023
Changes in the last 10 years (56)
| Mar 18, 2026 | Theodora Ross became Chief Development Officer |
| Jun 27, 2025 | Joshua Bleharski became Chief Financial Officer |
| Mar 28, 2025 | The company announced the departure of Susan L. Kelley from the board in an SEC filing |
| Dec 11, 2024 | Stuart Dorman became Chief Commercial Officer |
| Sep 18, 2024 | Douglas B. Snyder became SVP, General Counsel |
| Jun 21, 2024 | The company announced the departure of Jason Throne as Chief Legal Officer in an SEC filing |
| Sep 21, 2023 | The company announced the departure of Paul A. Stone as Chief Financial Officer in an SEC filing |
| Jul 1, 2023 | Briseno Andres Ruiz became Title: SVP, Head of Finance and Investor Relations |
| Feb 28, 2023 | Paul A. Stone listed as Chief Financial Officer (previously SVP, Chief Financial Officer) in SEC filings |
| Feb 28, 2023 | Michael Anthony White listed as Chief Scientific Officer (previously SVP, Chief Scientific Officer) in SEC filings |
| Feb 28, 2023 | Jason Throne listed as Chief Legal Officer (previously SVP, General Counsel) in SEC filings |
| Feb 28, 2023 | Darrin Beaupre listed as Chief Medical Officer (previously SVP, Chief Medical Officer) in SEC filings |
| Dec 9, 2022 | Darrin Beaupre became SVP, Chief Medical Officer |
| Apr 5, 2022 | Catherine J Mackey became a director |
| Oct 25, 2021 | Michael Anthony White became SVP, Chief Scientific Officer |
| Feb 12, 2021 | Susan L. Kelley became a director |
| Feb 4, 2021 | Mark N Lampert reported in an SEC filing no longer being a 10% owner |
| Feb 4, 2021 | Bvf Partners L P/il reported in an SEC filing no longer being a 10% owner |
| Feb 4, 2021 | Bvf Inc/il reported in an SEC filing no longer being a 10% owner |
| Dec 15, 2020 | Paul A. Stone listed as SVP, Chief Financial Officer (previously Chief Financial Officer) in SEC filings |
| Nov 13, 2020 | Scott M Rocklage reported in an SEC filing no longer being a 10% owner |
| Nov 13, 2020 | John D Diekman reported in an SEC filing no longer being a director |
| Nov 13, 2020 | Andrew J. Schwab reported in an SEC filing no longer being a 10% owner |
| Nov 13, 2020 | 5AM Ventures IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 13, 2020 | 5AM Partners IV, LLC reported in an SEC filing no longer being a 10% owner |
| Nov 13, 2020 | 5AM Co-Investors IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 2, 2020 | Jason Throne listed as SVP, General Counsel (previously VP, General Counsel) in SEC filings |
| Jun 26, 2020 | Malcolm Garret Hampton became a director |
| Jun 18, 2020 | Mark N Lampert became a 10% owner |
| Jun 18, 2020 | Bvf Partners L P/il became a 10% owner |
| Jun 18, 2020 | Bvf Inc/il became a 10% owner |
| Feb 25, 2020 | Paul A. Stone listed as Chief Financial Officer (previously SVP, General Counsel) in SEC filings |
| Dec 17, 2019 | Wendy L Yarno became a director |
| Oct 9, 2019 | Jason Throne became VP, General Counsel |
| May 30, 2019 | Alexandria Venture Investments, LLC reported in an SEC filing no longer being a 10% owner |
| May 22, 2019 | Yujiro S Hata became a director |
| May 22, 2019 | Yujiro S Hata became President and CEO |
| May 22, 2019 | Timothy M Shannon became a director |
| May 22, 2019 | Thilo Schroeder became a director |
| May 22, 2019 | Terry J Rosen became a director |
| May 22, 2019 | Scott W Morrison became a director |
| May 22, 2019 | Scott M Rocklage became a 10% owner |
| May 22, 2019 | Paul A. Stone became SVP, General Counsel |
| May 22, 2019 | Michael P. Dillon became SVP, Chief Scientific Officer |
| May 22, 2019 | Mark Lackner became SVP, Head of Biology |
| May 22, 2019 | Julie Hambleton became SVP, Chief Medical Officer |
| May 22, 2019 | John D Diekman became a director |
| May 22, 2019 | Jeffrey Stein became a director |
| May 22, 2019 | Jeffrey Hager became SVP, Chief Technology Officer |
| May 22, 2019 | Canaan X L.p. became a 10% owner |
| May 22, 2019 | Canaan Partners X LLC became a 10% owner |
| May 22, 2019 | Andrew J. Schwab became a 10% owner |
| May 22, 2019 | Alexandria Venture Investments, LLC became a 10% owner |
| May 22, 2019 | 5AM Ventures IV, L.P. became a 10% owner |
| May 22, 2019 | 5AM Partners IV, LLC became a 10% owner |
| May 22, 2019 | 5AM Co-Investors IV, L.P. became a 10% owner |
Not reported recently (8)
- Timothy M Shannon · Last reported as a director in an SEC filing dated Jun 9, 2023
- Michael P. Dillon · Last reported as SVP, Chief Scientific Officer in an SEC filing dated Oct 7, 2021
- Mark Lackner · Last reported as SVP, Head of Biology in an SEC filing dated Feb 26, 2021
- Julie Hambleton · Last reported as SVP, Chief Medical Officer in an SEC filing dated Feb 25, 2020
- Jeffrey Hager · Last reported as SVP, Chief Technology Officer in an SEC filing dated Jul 30, 2019
- Canaan X L.p. · Last reported as a 10% owner in an SEC filing dated May 28, 2019
- Canaan Partners X LLC · Last reported as a 10% owner in an SEC filing dated May 28, 2019
- Thilo Schroeder · Last reported as a director in an SEC filing dated May 22, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
IDYA Proposed Insider Sales (Form 144)
Latest: 2026-10-06
? Form 144 Guide
Last 30d:
1 filing
· $8.8M notice value
· Last 90d:
1 filing
· $8.8M notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
YUJIRO HATA (1, $8.8M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-06 | YUJIRO HATA | CEO | 230,316 | $8.80M | 2026-10-06 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-07-07 | Andres Ruiz Briseno | Senior VP | 9,550 | $382.1K | 2026-07-07 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2024-08-26 | Jason Throne | Former Officer | 75,000 | $3.02M | 2024-08-26 | J.P. Morgan Securities LLC | — | EDGAR |
| 2024-05-29 | Michael White | Officer | 28,500 | $1.05M | 2024-05-29 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2024-05-14 | YUJIRO HATA | CEO | 175,000 | $7.24M | 2024-05-14 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2024-02-09 | Andres Ruiz Briseno | Senior VP | 14,867 | $677.9K | 2024-02-09 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2024-02-01 | YUJIRO HATA | CEO | 100,000 | $4.50M | 2024-02-01 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2024-01-12 | Andres Ruiz Briseno | Senior VP | 4,000 | $149.5K | 2024-01-12 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2024-01-12 | YUJIRO HATA | CEO | 75,000 | $3.00M | 2024-01-12 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2023-12-27 | Paul Stone | Officer | 55,680 | $1.95M | 2023-12-27 | J.P. Morgan Securities LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
75 ETFs hold IDYA
25 shown · $493.21M total exposure · 0.10% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $120.1M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.11% | $80.9M | $75.1B | 2026-10-20 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.56% | $58.5M | $10.4B | 2026-10-20 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.04% | $41.9M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.19% | $26.7M | $13.7B | 2026-10-20 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.23% | $24.6M | $11.0B | 2026-10-20 |
| 7 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.07% | $22.4M | — | 2026-10-20 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.11% | $20.3M | — | 2026-09-30 |
| 9 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $12.5M | — | 2026-05-31 |
| 10 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $11.2M | — | 2026-10-20 |
| 11 | VHT Vanguard Health Care ETF | Vanguard | 0.05% | $10.1M | — | 2026-09-30 |
| 12 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.13% | $9.7M | — | 2026-10-20 |
| 13 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 2.55% | $8.3M | $325.4M | 2026-10-20 |
| 14 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.22% | $6.8M | $3.1B | 2026-10-20 |
| 15 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.47% | $6.4M | $1.3B | 2026-10-20 |
| 16 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $5.0M | $97.4B | 2026-10-20 |
| 17 | CANC Tema Oncology ETF | Nport | 2.27% | $4.0M | — | 2026-05-31 |
| 18 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.06% | $4.0M | $6.6B | 2026-10-20 |
| 19 | FSMD Fidelity Small-Mid Multifactor ETF | Fidelity | 0.13% | $3.2M | $2.5B | 2026-10-20 |
| 20 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.23% | $3.1M | $1.4B | 2026-10-20 |
| 21 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.21% | $2.9M | — | 2026-09-30 |
| 22 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.02% | $2.9M | $13.6B | 2026-10-20 |
| 23 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.01% | $2.8M | — | 2026-10-20 |
| 24 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.65% | $2.7M | — | 2026-05-31 |
| 25 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.37% | $2.4M | — | 2026-10-21 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.94
TTM Revenue
$234.13M
TTM Net Income
$-175.02M
TTM Op. Cash Flow
$-111.66M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $8.86M | $-112.45M | $-1.22 | $-88.21M |
| Q1 '26 | 2026-03-31 | $6.56M | $-98.54M | $-1.11 | $-75.17M |
| Q4 '25 | 2025-12-31 | $10.88M | $-83.27M | $-0.94 | $-90.50M |
| Q3 '25 | 2025-09-30 | $207.83M | $119.24M | $1.33 | $142.21M |
| Q2 '25 | 2025-06-30 | — | $-77.49M | $-0.88 | $-62.47M |
| Q1 '25 | 2025-03-31 | — | $-72.18M | $-0.82 | $-60.34M |
| Q4 '24 | 2024-12-31 | $7.00M | $-130.31M | $-1.55 | $-121.66M |
| Q3 '24 | 2024-09-30 | — | $-51.82M | $-0.60 | $-49.23M |
| Q2 '24 | 2024-06-30 | — | $-52.77M | $-0.68 | $-32.88M |
| Q1 '24 | 2024-03-31 | — | $-39.57M | $-0.53 | $-43.81M |
| Q4 '23 | 2023-12-31 | $3.92M | $-33.95M | $-0.52 | $-23.75M |
| Q3 '23 | 2023-09-30 | $8.04M | $-27.44M | $-0.46 | $-30.17M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.65
P/S
13.59
EV/EBITDA
—
EV/Sales
12.43
ROE
-14.6%
ROA
-13.4%
Div Yield
0.00%
FCF Yield
-3.51%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$3.18B
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.18M
SI % of Float
10.55%
Days to Cover
8.43
Short Vol Ratio
72.8%
Free Float
87.08M
Float %
99.1%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-05-13